Loading...
Market
Will Daiichi Sankyo-Merck's patritumab deruxtecan receive FDA approval by December 31, 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcement or press release
Story
Daiichi Sankyo-Merck's Patritumab Deruxtecan Meets Main Goal in Phase 3 Trial
Sep 17, 2024, 10:04 AM
Daiichi Sankyo and Merck have announced that their cancer drug, patritumab deruxtecan, has met the main goal in a Phase 3 late-stage trial for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The drug, described as a 'guided-missile' cancer treatment, shows promise in targeting specific cancer cells. This development comes as Daiichi Sankyo aims to advance its next generation of targeted oncology drugs, potentially without the need for a partner.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
